• Oral
• Rectal
• Transdermal and Nasal
• Intravenous or Subcutaneous

Chapter three: Issues and Trends

• Overview
• Geographical Trends
  • United States
  • European Union
  • Japan
  
  
• Regulatory Authorities
  • Clinical Trials
  • New Indications
  
  
• Lifestyle and Social Issues
• Barriers to Adjunctive Therapies
• Drug Delivery Advancements
• Pain Management Measures
• Oxycontin Issues
• Cancer-Related Fatigue Issues
• Individualized Chemotherapy
• Chemotherapy and Memory Loss

chapter Four: Antinauseants and Antiemetics

• Overview
• Products
  • Serotonin Receptor Antagonists
  • Phenothiazines
  • Metoclopramide and Other Drugs
  
  
• Drug Delivery Methods for Antinauseants and Antiemetics
• Research and Development
• Market Overview
• Competitive Analysis

chapter Five: Pain Management

• Overview
  • Pain Pathways
  • Primary Cancer Pain
  • Breakthrough Cancer Pain
  
  
• Cancer Pain Delivery Methods
  • Oral
  • Oral Transmucosal
  • Parenteral
  • Transdermal
  • Rectal
  • Intranasal
  
  
• Description of Products
  • Primary Cancer Pain Medications
  • Non-Narcotic Analgesics
  • Narcotic Analgesics
  • Breakthrough Cancer Pain Medications
  • Antidepressants
  • Anticonvulsants
  • Corticosteroids
  • Bisphosphonates and Calcitonins
  • Radiopharmaceuticals
  • Other
  
  
• Research and Development
• Market Overview
• Competitive Analysis

chapter six: Biological Response Modifiers

• Overview
  • Description of Products
    • Hematopoietic Growth Factors
    • Granulocyte Colony-Stimulating Factor (G-CSF)
    • Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF)
    • Epoetin Alpha
    • Darbepoetin Alfa
    • Epoetin Beta
    • Human keratinocyte growth factor
    • Cytomodulatory Agents
    
    
  • Research and Development
  • Market Overview
  • Competitive Analysis

chapter seven: Infection Control

• Overview
• Description of Products
  • Anti-Bacterials and Antivirals
  • Antifungals
  
  
• Research and Development
• Market Overview
• Competitive Analysis

chapter eight: Other Adjunctive Therapies

• Overview
• Fatigue
• Anorexia/Cachexia/Weight Loss
• Diarrhea
• Constipation
• Alopecia (Hair Loss)
• Radiation-Induced Dermatitis
• Other

• Fatigue
• Anorexia/Cachexia/Weight Loss
• Diarrhea
• Constipation
• Hair Loss
• Radiation-Induced Dermatitis
• Research and Development
• Market Overview
• Competitive Analysis

Chapter Nine: Market Summary

• Overview
• Market Size
• Competitive Analysis
• Market Analysis

chapter Ten: Company Profiles

• Introduction
• Competitive Summary
• Abbott Laboratories
• Amgen, Inc.
• Bayer Corp.
• Cephalon , Inc
• Chugai Pharmaceutical Company Ltd.
• Eli Lilly & Co.
• GlaxoSmithKline plc
• Johnson & Johnson
• Novartis Pharmaceuticals Corp.
• Pfizer, Inc.
• Roche Group
• Sanofi -Aventis

APPENDIX: Company Directory

List of Exhibits

Chapter one: Executive Summary

• Table 1-1: Cancer Incidence and Deaths as a Percentage to Population by Selected Country/Region 2005
• Table 1-2: Summary Table: The World Market for Adjunctive Therapies in Cancer Revenues and Growth Rate 2003-2010 Figure 1-1: Summary Figure: The World Market for Adjunctive Therapies in Cancer 2003-2010

Chapter Two: Introduction

• Table 2-1: List of Cancers
• Table 2-2: Side Effects Associated with Chemotherapy Table 2-3: Side Effects Associated with Radiation Therapy Table 2-4: Population by Country 2003-2010 Figure 2-1: Population by Major Market Country 2005 vs. 2010 Table 2-6: Cancer Incidence and Mortality by Major Market Country 2005 Figure 2-3: Cancer Incidence by Major Market Country 2005 Figure 2-4: Cancer Deaths by Major Market Country 2005 Table 2-8: Cancer Incidence and Deaths as a Percentage to Population by Selected Major Market Country/Region

chapter Four: Antinauseants and Antiemetics

• Figure 4-1: Incidence of Emesis in Cancer Patients
• Table 4-1: Chemotherapy Agents and Level of Emetic Potential
• Table 4-2: Time Course of Selected Products in Nausea and Vomiting
• Table 4-3: Selected Prescription Antinauseants/Antiemetics by Available Delivery Method
• Table 4-4: Antinauseants and Antiemetics in Development for Treatment of Cancer related Nausea and Vomiting
• Table 4-5: The Adjunctive Antinauseant and Antiemetic Market 2003-2010
• Figure 4-1: The Adjunctive Antinauseant and Antiemetic Market 2003-2010
• Table 4-6: The Adjunctive Antinauseant and Antiemetic Market, Estimated Sales by Geographic Region, 2005
• Figure 4-2: The Adjunctive Antinauseant and Antiemetic Market by Geographic Region, 2005
• Table 4-7: Leading Suppliers’ Revenues and Share of the Antinauseants and Antiemetics Segment 2005
• Figure 4-3: Leading Suppliers’ Shares of the Antinauseants and Antiemetics Segment 2005

chapter Five: Pain Management

• Figure 5-1: Incidence of Pain in Cancer Patients
• Table 5-1: The World Health Organization Three-Step Analgesic Ladder
• Table 5-2: Selected Prescription Non-Narcotic Analgesics by Available Delivery Method
• Table 5-3: Selected Over-the-Counter Non-Narcotic Analgesics by Available Delivery Method
• Table 5-4: Selected Prescription Narcotic Analgesics by Available Delivery Method
• Table 5-5: Selected Prescription Antidepressants Used for Cancer Pain by Available Delivery Method
• Table 5-6: Selected Prescription Anticonvulsants Used for Cancer Pain by Available Delivery Method
• Table 5-7: Selected Prescription Corticosteroids Used for Cancer Pain by Available Delivery Method
• Table 5-8: Selected Prescription Bisphosphonates and Calcitonins Used for Cancer Pain by Available Delivery Method
• Table 5-9: Selected Prescription Radiopharmacuticals Used for Cancer Pain by Available Delivery Method
• Table 5-10: Pain Management Products in Development for Treatment of Cancer Related Pain
• Table 5-3: The Adjunctive Pain Management Market 2003-2010
• Figure 5-1: The Adjunctive Pain Management Market 2003-2010
• Table 5-4: The Adjunctive Pain Management Market, Estimated Sales by Geographic Region, 2005
• Figure 5-2: The Adjunctive Pain Management Market by Geographic Region, 2005
• Table 5-5: Leading Suppliers’ Revenues and Shares of the Cancer Pain Management Segment 2005
• Figure 5-3: Leading Suppliers’ Shares of the Cancer Pain Management Segment 2005

chapter six: Biological Response Modifiers

• Figure 6-1: Frequency of Bone Marrow Suppression in Cancer Patients
• Table 6-1: Selected Biological Response Modifiers and Available Delivery Method
• Table 6-2: Biological Response Modifiers in Development for Treatment of Cancer Related Infection
• Table 6-3: The Adjunctive Biological Response Modifier Market 2003-2010
• Figure 6-2: The Adjunctive Biological Response Modifier Market 2003-2010
• Table 6-4: The Adjunctive Biological Response Modifier Market, Estimated Sales by Geographic Region, 2005
• Figure 6-3: The Adjunctive Biological Response Modifier Market, Market by Geographic Region, 2005
• Table 6-5: Leading Suppliers’ Revenues and Shares of the Biological Response Modifiers Segment 2005
• Figure 6-4: Leading Suppliers’ Market Share of the Biological Response Modifiers Segment 2005

chapter seven: Infection Control

• Table 7-1: Common Infection Sites and Organisms
• Figure 7-1: Frequency of Infection in Cancer Patients
• Table 7-2: Selected Prescription Antibacterial and Antiviral Agents and Available Delivery Method
• Table 7-3: Selected Prescription Antifungals and Available Delivery Method
• Table 7-4: Anti-Infective Agents and Antifungals in Development for Treatment of Cancer related Infection
• Table 7-3: The Adjunctive Infection Control Market 2003-2010 Figure 7-1: The Adjunctive Infection Control Market 2003-2010
• Table 7-4: The Adjunctive Infection Control Market Estimated Sales by Geographic Region, 2005
• Figure 7-2: The Adjunctive Infection Control Market by Geographic Region, 2005
• Table 7-5: Leading Suppliers’ Revenues and Shares of the Infection Control Segment 2005
• Figure 7-3: Leading Suppliers’ Market Shares of the Infection Control Segment 2005

chapter eight: Other Adjunctive Therapies

• Figure 8-1: Frequency of Fatigue in Cancer Patients
• Figure 8-2: Incidence of Anorexia/ Cachexia/Weight Loss in Cancer Patients
• Figure 8-3: Incidence of Diarrhea in Cancer Patients
• Figure 8-4: Incidence of Constipation in Cancer Patients
• Table 8-1: Selected Chemotherapy Agents and Level of Hair Loss Potential
• Figure 8-5: Frequency of Hair Loss in Cancer Patients
• Figure 8-6: Prevalence of Other Conditions in Cancer Patients (Sexual/ Reproductive, Heart, Liver, Lung, Nerve, Kidney/Urinary Damage)
• Table 8-2: Selected Prescription and Non-prescription Products to Minimize Symptoms of Fatigue in Cancer Patients and Their Available Delivery Method
• Table 8-3: Selected Prescription Products for the Treatment of Anorexia/ Cachexia in Cancer Patients and Available Delivery Method
• Table 8-4: Selected Prescription and Non-prescription Products for the Treatment of Diarrhea in Cancer Patients and Available Delivery Method
• Table 8-5: Selected Prescription and Non-prescription Products for the Treatment of Constipation in Cancer Patients and Available Delivery Method
• Table 8-6: Selected Prescription and Non-prescription Products for the Treatment of Radiation-induced Dermatitis
• Table 8-7: Other Adjunctive Therapies in Development for Treatment of Cancer
• Table 8-8: The Adjunctive Therapy Other Products Market 2003-2010
• Figure 8-7: The Adjunctive Therapy Other Products Market 2003-2010
• Table 8-9: The Adjunctive Therapy Other Products Market, Estimated Sales by Geographic Region, 2005
• Figure 8-8: The Adjunctive Therapy Other Products Market by Geographic
• Region, 2005

Chapter Nine: Market Summary

• Table 9-1: The World Market for Adjunctive Therapies in Cancer 2003-2010
• Figure 9-1: The World Market for Adjunctive Therapies in Cancer 2003-2010
• Table 9-2: The Global Market for Adjunctive Therapies in Cancer by Type, 2003-2010
• Figure 9-2: The World Market for Adjunctive Therapies in Cancer Revenues by Type 2003-2010
• Figure 9-3: The World Market for Adjunctive Therapies in Cancer Estimated Market Share by Product Type 2005
• Table 9-5: Leading Suppliers, Products, and Segments of Participation 2005